Skip to content

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of "Hold" from Analysts – MarketBeat

Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRXGet Rating) has been assigned a consensus recommendation of “Hold” from the ten analysts that are currently covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $18.29.
A number of equities analysts recently issued reports on BCRX shares. Barclays upped their price objective on shares of BioCryst Pharmaceuticals from $12.00 to $14.00 and gave the stock an “equal weight” rating in a research report on Friday, August 5th. Cantor Fitzgerald reissued an “overweight” rating on shares of BioCryst Pharmaceuticals in a report on Monday, May 9th. Oppenheimer lowered shares of BioCryst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Friday, August 5th. Evercore ISI lowered shares of BioCryst Pharmaceuticals from an “outperform” rating to an “in-line” rating and set a $14.00 target price on the stock. in a report on Friday, August 5th. Finally, Piper Sandler reduced their target price on shares of BioCryst Pharmaceuticals from $24.00 to $19.00 in a report on Thursday, May 5th.

BioCryst Pharmaceuticals Price Performance

BCRX stock opened at $13.90 on Thursday. The company has a 50 day simple moving average of $12.43 and a 200 day simple moving average of $12.64. The stock has a market cap of $2.58 billion, a price-to-earnings ratio of -12.09 and a beta of 2.20. BioCryst Pharmaceuticals has a 1 year low of $7.61 and a 1 year high of $19.99.
BioCryst Pharmaceuticals (NASDAQ:BCRXGet Rating) last released its quarterly earnings data on Thursday, August 4th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.04. During the same quarter last year, the firm earned ($0.24) EPS. On average, equities research analysts anticipate that BioCryst Pharmaceuticals will post -1.23 EPS for the current fiscal year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. Diversified Trust Co boosted its stake in shares of BioCryst Pharmaceuticals by 6.6% in the 2nd quarter. Diversified Trust Co now owns 19,408 shares of the biotechnology company’s stock valued at $205,000 after purchasing an additional 1,200 shares during the last quarter. Semmax Financial Advisors Inc. boosted its stake in BioCryst Pharmaceuticals by 389.6% during the first quarter. Semmax Financial Advisors Inc. now owns 1,699 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 1,352 shares in the last quarter. Arizona State Retirement System boosted its stake in BioCryst Pharmaceuticals by 2.9% during the second quarter. Arizona State Retirement System now owns 50,043 shares of the biotechnology company’s stock worth $529,000 after acquiring an additional 1,403 shares in the last quarter. E Fund Management Co. Ltd. boosted its stake in BioCryst Pharmaceuticals by 11.8% during the first quarter. E Fund Management Co. Ltd. now owns 16,641 shares of the biotechnology company’s stock worth $271,000 after acquiring an additional 1,756 shares in the last quarter. Finally, Strs Ohio bought a new position in BioCryst Pharmaceuticals during the first quarter worth $32,000. 80.68% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

(Get Rating)
BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

Featured Stories

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BioCryst Pharmaceuticals, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and BioCryst Pharmaceuticals wasn’t on the list.
While BioCryst Pharmaceuticals currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Complete the form below to receive the latest headlines and analysts’ recommendations for your stocks with our free daily email newsletter:
Tom remains optimistic about investors’ prospects going forward, even as the market reacts to the words of Fed Chair Jerome Powell about “pain ahead.”
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.
Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.
Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.
As Featured By:
MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.
Twitter Facebook StockTwits Financial Juice YouTube
MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot
© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.

source

Share:

Pulse Handshak

Pulse Handshak

Collaborative online survey tool for the market research industry. Remote assisted surveying just like face-to-face interviews. Here interviewers can talk to the respondent over the web-console without the need for any other communication channel and share the same Q're with responses and click actions.

Pulse FE

Pulse FE

Pulse Field Expert or Pulse FE is the main platform for both offline and online survey at softofficepro.com. It is robust and used by hundreds of clients over tens of years with millions of responses. Do it once Q're and deploy on both offline devices (android) and online forms makes it a great cost effective platform for any kind of responses

Pulse Ultimate

Pulse Ultimate

Pulse Ultimate is targeted for tracking studies and retail audits. An offline survey system offering extreme field control including processes like data quality check, back-check, rework, comparison with previous wave data etc. helps to get the best results on a day-to-day basis

More Posts